Compare Cassava Sciences Inc (FLNA) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while State Street Technology Select Sector SPDR ETF trades at $188.71. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | XLK | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.64 | $198.21 |
52-Week Low | $0.87 | $127.49 |
Enterprise Value | -$34.93M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
XLK trades at $188.86, up 1.36% with a bullish technical signal from moving averages. The ETF shows strong momentum near resistance at $189, supported by sector inflows and earnings growth. Recent news highlights tech sector leadership and investor accumulation during selloffs, though concentration risk remains a concern.
Outlook is positive with tech earnings driving gains, but overbought RSI and high dependence on mega-caps pose near-term risks. Long-term growth hinges on AI adoption and sector diversification, with analysts favoring broad tech exposure alternatives for valuation advantages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
